Galmed Pharmaceuticals (GLMD) EPS (Basic) (2013 - 2020)

Galmed Pharmaceuticals' EPS (Basic) history runs 8 years deep, the most recent figure standing at $23658.6 for Q1 2020.

• In Q1 2020, EPS (Basic) fell 12.34% year-over-year to $23658.6; the TTM figure through Dec 2020 stood at $23658.6 (down 45.38% YoY), while the FY2025 annual figure was $2.39, down 70.42% from the prior year.
• EPS (Basic) was $23658.6 for Q1 2020 at Galmed Pharmaceuticals, up from $8542.3 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $26988.2 in Q1 2019 to a low of $2247.2 in Q3 2018.
• Historically, EPS (Basic) has averaged $9599.2 across 5 years, with a median of $7782.8 in 2019.
• The sharpest annual moves came in 2018 and 2019: EPS (Basic) sank 43.04% in 2018, then surged 246.33% in 2019.
• A 5-year view of EPS (Basic) shows it stood at $3238.9 in 2016, then advanced by 14.8% to $3718.4 in 2017, then surged by 84.57% to $6863.0 in 2018, then increased by 24.47% to $8542.3 in 2019, then surged by 176.96% to $23658.6 in 2020.
• The last three EPS (Basic) figures came in at $23658.6 (Q1 2020), $8542.3 (Q4 2019), and $7782.8 (Q3 2019), per Business Quant data.